A Scottish biotechnology company has reported that a new gene therapy technology improves outcomes of glaucoma surgery.
The research, which was published in Molecular Therapy, described the use of NanoGenics’ LipTide technology.
LipTide is a peptide-based nanoparticle that can be modified to target different cell types.
The technology addresses a current pitfall in glaucoma surgery where a tiny whole inserted in the base of the eye closes through the body’s own healing mechanisms.
This natural process means that the traditional trabeculectomy procedure fails half of the time.
Cytotoxic agents are used to prevent the hole from closing but these drugs have a poor safety profile.
The new study found that when used in animals, LipTide produces the same effect as cytotoxic agents with reduced scarring and no side effects.